Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

MedicilonHengruiPhama

More Like This

ACCESSWIRE associated0

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

PR Newswire associated0

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

PR Newswire associated0

Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Business Wire logo

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers